Jeff Cranmer @jeff_cranmer

Executive Editor, BioCentury; Host, BioCentury This Week podcast. Jersey boy happily ensconced in Cali. Dad. Iggles fan. Cats. @Princeton, @SAISHopkins alum. linkedin.com/in/jeff-cranme… San Carlos, Calif. Joined October 2014

Tweets

5K
Followers

3K
Following

1K
Likes

8K

Jeff Cranmer @jeff_cranmer

4 days ago

Scoop via @BioCentury's @steveusdin1: @CMSGov to propose 'most favored nation' pricing benchmark model. White House reviewing proposed international reference pricing model biocentury.com/article/657090

0 0 1 211 0

Adam Feuerstein ✡️ @adamfeuerstein

a week ago

FDA approves Stealth Biotherapeutics' Forzinity, first treatment for Barth Syndrome

7 13 62 19K 8

Jeff Cranmer @jeff_cranmer

a week ago

Restricting U.S. in-licensing from China could spark a global IP arms race, hurting patients and U.S. biotech companies, @NEA's @ScottGottliebMD warns. via @BioCentury's @steveusdin1 biocentury.com/article/657051

2 1 3 347 0

Jeff Cranmer @jeff_cranmer

2 weeks ago

$LBRX's IPO 1st to raise >$25M by a pure-play biopharma on @Nasdaq since $AARD in February & at $285M it's 2nd largest of '25 after $MTSR. @lb_pharma finishes the day up 12%.

1 0 4 650 0

Jeff Cranmer @jeff_cranmer

3 weeks ago

House passes bill seeking to end most U.S.-China academic research collabs. @steveusdin1 says like Biosecure, the SAFE Research Act is part of a trend in DC to re-define nat security to include basic, applied research on topics such as cancer biocentury.com/article/656978

0 1 2 608 1

Jeff Cranmer @jeff_cranmer

3 weeks ago

U.K. nds to find common ground with pharmas on reimbursement if it wants to win the competition for life sciences investments. Fortunately for @MHRAgovuk CEO Lawrence Tallon creating a world-class reg environment, is less contentious. via @steveusdin1 biocentury.com/article/656960

0 0 2 197 0

Jeff Cranmer @jeff_cranmer

4 weeks ago

On latest #BioCenturyThisWeek pod: @BioBonanos on @JMaraganore, Meanwell newco to develop AI guided early risk assessment tool for CV, @SteveUsdin on @US_FDA's Prasad disrupting vax status quo & @FishburnSimone's take on resilience in biotech & tennis, @usopen & @naomiosaka

0 0 3 273 0

Jeff Cranmer @jeff_cranmer

a month ago

Amy Peterson is out as CMO of @ExelixisInc. The cancer company named Dana Aftab, who was EVP, discovery and translational research and CSO, EVP R&D

0 0 2 203 0

Jeff Cranmer @jeff_cranmer

a month ago

A rare biotech filing for a NASDAQ IPO appeared late Friday from LB Pharmaceuticals Inc. The neuro play has raised $122M to date; top shareholders include Deep Track Capital, Vida Ventures, Pontifax and TCG Crossover. h/t @BioBonanos

0 0 5 384 0

Jeff Cranmer @jeff_cranmer

a month ago

After delays & an about-face on reconsidering a CRL, @US_FDA will now conduct exceptionally quick review of Stealth BioTherapeutics' treatment for #Barthsyndrome. Does the move signal the agency's changing stance on rare disease therapies? via @BioBonanos biocentury.com/article/656827

0 0 3 176 0

Jeff Cranmer @jeff_cranmer

2 months ago

Just when u thought it was safe to go back in the water - it's baaack. Sens. reviving Biosecure via an amendment in must-pass Defense bill that seeks disengagement with Chinese biotechs, attempts to address concerns that killed Biosecure. via @steveusdin1 biocentury.com/article/656707

0 2 6 795 0

Jeff Cranmer @jeff_cranmer

2 months ago

It will take @US_FDA 24 mo to review data from 12 #BarthSyndrome pts. @StealthBT doesn’t know if it can stay in business that long. Will another patient group be able to sway @realDonaldTrump's #FDA to make good on rare dis. promises? @steveusdin1 reports: biocentury.com/article/656691

0 0 3 157 1

Jeff Cranmer @jeff_cranmer

2 months ago

I knew it! Dan for Warwick was right.

Eli Manning @EliManning

2 months ago

I knew it! Dan for Warwick was right.

122 531 8K 556K 479

Download Video

0 0 1 345 0

Jeff Cranmer @jeff_cranmer

2 months ago

Prasad’s downfall signals a shift to libertarian regulation: The challenge for industry and patients is to couple misplaced enthusiasm for right-to-try with science-based approaches to generating evidence. A Perspective from @BioCentury's @steveusdin1: biocentury.com/article/656645

0 0 1 201 0

Jeff Cranmer @jeff_cranmer

2 months ago

Prasad's ouster from @US_FDA raises prospect of CBER reset: Uncertainty fueled by ideology, politics is increasing, but when dust settles industry and advocates may be happier, says @steveusdin1 in @BioCentury: biocentury.com/article/656627

1 1 4 485 0

Jeff Cranmer @jeff_cranmer

2 months ago

Sunday's deal between @GSK and Hengrui for up to 12 assets is 1 of the clearest signs yet that cross-border, East-West deals have been undergoing a foundational shift. @BioPharmaJosh and I take a look at why this deal is so important in @BioCentury: biocentury.com/article/656602

0 0 2 234 0

Jeff Cranmer @jeff_cranmer

2 months ago

Leads Biolabs' offering is the 16th biotech IPO on an East Asian exchange this year, 9 of which have been on the HKSE. 7 of those nine have come since mid-April. That compares with 11 biotech IPOs on NASDAQ in 2025.

0 0 1 210 0

Jeff Cranmer @jeff_cranmer

2 months ago

Always knew Ozzy had a sweet tooth but thought it was for the leaf. h/t @BioBonanos

0 0 1 193 0

Download Image

Jeff Cranmer @jeff_cranmer

2 months ago

First clinical evidence spurs @sanofi takeout of @medicxi best in class vax play Vicebio for $1.15B up front. via @BioBonanos: biocentury.com/article/656546

0 1 4 868 0

Jeff Cranmer @jeff_cranmer

3 months ago

A leaked memo on @IAmBiotech strategy is energizing anti-vaxxers, writes @BioCentury's @steveusdin1. Document describes BIO's investment in pro-vaccine communications, plans to engage with conservatives in and outside the Trump administration biocentury.com/article/656351